Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland | Citedby Results | Respiration | Karger Publishers

Skip to Main Content

Skip Nav Destination

Long-Term Benefits of Inhaled Tobramycin in Children with Cystic Fibrosis: First Clinical Observations from Poland

Respiration (2008) 75 (2): 178–181.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Treatment of Pseudomonas and Staphylococcus Bronchopulmonary Infection in Patients with Cystic Fibrosis

Rashmi Ranjan Das
Sushil Kumar Kabra
Meenu Singh
A. Sihoe
F. Varoli

The Scientific World Journal (2013) 2013 (1)

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease

Donald R VanDevanter
Michael W Konstan

Clinical Investigation (2012) 2 (2): 163.

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis

Geraint B. Rogers
Lucas R. Hoffman
Gerd Döring

Journal of Cystic Fibrosis (2011) 10 (6): 387.

Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms

Carole Nagant
Marie Tré-Hardy
Malika El-Ouaaliti
Paul Savage
Michel Devleeschouwer
Jean-Paul Dehaye

Applied Microbiology and Biotechnology (2010) 88 (1): 251.

Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa

M. Alipour
Z. E. Suntres
A. Omri

Journal of Antimicrobial Chemotherapy (2009) 64 (2): 317.

Inhaled antimicrobial therapies for respiratory infections

Shin-Woo Kim
Joseph L. Kuti
David P. Nicolau

Current Infectious Disease Reports (2008) 10 (1): 29.